Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia.

Autor:	Maini K; Louisiana State University Shreveport, LA., Hollier JW; Louisiana State University Shreveport, LA., Gould H; Louisiana State University Shreveport School of Medicine, Shreveport, LA., Bollich V; Louisiana State University Shreveport School of Medicine, Shreveport, LA., John LaForge J; Louisiana State University Shreveport School of Medicine, Shreveport, LA., Cornett EM; Louisiana State University Shreveport, LA., Edinoff AN; Louisiana State University Shreveport, LA., Kaye AM; Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA., Kaye AD; Louisiana State University Shreveport, LA.
Jazyk:	angličtina
Zdroj:	Health psychology research [Health Psychol Res] 2021 Jun 19; Vol. 9 (1), pp. 24932. Date of Electronic Publication: 2021 Jun 19 (Print Publication: 2021).
DOI:	10.52965/001c.24932
Abstrakt:	Purpose of Review: This is a comprehensive review of the literature regarding the use of Lumateperone tosylate for schizophrenia. This review presents the background, evidence, and indications for the use of lumateperone tosylate in the treatment of schizophrenia. Recent Findings: Schizophrenia is a chronic mental health disorder that affects approximately 3.3 million people in the United States. Its symptoms, which must be present more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication. Lumateperone is a selective and concurrent modulator of serotonin, dopamine, and glutamate, which all mediate or modulate serious mental illness. Summary: Schizophrenia is a complex, severe mental illness that affects how the brain processes information. There are many medications used to treat schizophrenia. One antipsychotic agent, lumateperone tosylate, is a newer agent that the FDA recently approved. The most common adverse effects are shown to be mild such as somnolence, constipation, sedation, and fatigue, with the 42 mg recommended dose. Lumateperone tosylate is an FDA-approved drug that can be given only at the 42mg dose once daily with no titration requirements. Competing Interests: None of the authors of this manuscript have any conflicts of interest
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu